Product pipeline and R&Dpositive · 4 filings
“Prepaid expenses increased $2.9 million from December 31, 2023 due to the increased research and development activity for abdakibart (AVTX-009).”10-K · Mar 23, 2026 ↗
Avalo Therapeutics, Inc.
AVTX
Market read
Avalo Therapeutics, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 21 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.
Company-5.7% todayVolume comparison unavailable
Market group0 of 21 activeOil & Gas and Biotech · unavailable
Disclosed network0 of 2 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- AVTX's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if AVTX's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 21 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.
Evidence that supports
No thresholded supportive filing evidence is available yet.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- AVTX's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods9
Price observations319
Usable filing statements106
Verified relationships2
Evidence supporting the case
- Product pipeline and R&D has repeated favorable evidence across 4 filings.
- Input and raw-material costs has repeated favorable evidence across 3 filings.
Evidence challenging the case
- Latest annual revenue changed -86.6% year over year.
- Operating margin changed -108066.1 percentage points in the latest annual period.
- Net margin changed -124676.6 percentage points in the latest annual period.
Questions before a position
- EV/sales is 5818% above the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context
Price as of Sep 10, 2026
17.166m-2.0%12m+77.8%24m—
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2021-12-31$5.4M-19.4%——
2022-12-31$18.1M+234.4%$-1063.00—
2023-12-31$1.9M-89.3%$-113.58—
2024-12-31$441,000-77.1%$-20.91—
2025-12-31$59,000-86.6%$-5.84—
What management says matters
Persistent and emerging business drivers
Input and raw-material costspositive · 3 filings
“CMC expenses increased due to raw material purchases and drug manufacturing activities to support the trial during the current year.”10-K · Mar 23, 2026 ↗
Supply chain and availabilitymixed · 3 filings
“Additionally, the 11,186.267 shares of Series C Preferred Stock issued as a result of the warrant exercise in the fourth quarter of 2024, with a carrying value of $ 133.0 million, was recognized as a component of permanent stockholders’ equity within addition…”10-K · Mar 23, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 3897.6× · EV/sales 3628.8×. Comparisons use only industry-matched filing peers.
Scenario scaffold
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
17.16-5.7% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for AVTX. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for AVTX. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind AVTX
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
LLYEli Lilly and CompanypartnerNov 6, 2025 ▾
“AVTX-009 26 Table of Contents On March 27, 2024, Avalo obtained the rights to an anti-IL-1β mAb (AVTX-009), including the world-wide exclusive license from Eli Lilly and Company (“Lilly”) (the “Lilly License Agreement”), pursuant to its acquisition of AlmataB…”
Depended on by
ANROAlto Neuroscience, Inc.partnerNov 12, 2025 ▾
“License Agreement with Cerecor In May 2021, we entered into a patent and know-how license agreement, or the Cerecor Agreement, with Cerecor Inc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 5 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
AVTX is currently a Follower in the organic co-movement group Oil & Gas and Biotech. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for AVTX; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.